Back to search results

AppleX™ Apple Extract for Inflammation and Healthy Aging

This study is looking at whether a daily capsule of AppleX™ Apple Extract can help reduce inflammation and support healthy aging in adults aged 45-70. AppleX™ contains natural compounds like fisetin, quercetin, and other plant-based nutrients. You might be able to join if you are between 45 and 70 years old, don't smoke, and show some signs of low-grade inflammation based on a questionnaire. The main goal is to see if AppleX™ lowers a blood marker for inflammation called high-sensitivity C-reactive protein (hsCRP) after 24 weeks. Researchers will also explore its effects on fatigue, joint comfort, and biological aging. The study is currently unclear on its recruitment status.

Study design
This interventional study plans to enroll 70 participants. You would either receive the AppleX™ Apple Extract or an inactive look-alike capsule (placebo).
What's involved
You would take a capsule once daily with breakfast for 24 weeks. Biological metrics will be collected remotely using home-based finger-prick blood samples.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint is measured at Week 24, which is the end of the treatment period.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07678346

Evaluation of AppleX™ Apple Extract on Anti-Inflammatory and Healthy Aging Effects

Not Yet Recruiting
NAAges 45–70InterventionalBasic science
Nutraland USA, Inc.
~70 participants
Updated 2026-07-01 on ClinicalTrials.gov
What's tested:Apple ExtractPlacebo

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change from Baseline in High-Sensitivity C-Reactive Protein (hsCRP) at Week 24
Measured over Baseline (Week 0) and Week 24

Conditions

Systemic Inflammation (hsCRP)
Healthy Aging
Vitality
Healthy Adult Participants

Explore related trials

Healthy AgingSystemic autoinflammation

Where it's being run

1 sites across 1 states
California1

Study leadership

  • Dr. Bill Clark, PhD · PRINCIPAL_INVESTIGATOR · Natprologix, LLC

Who to contact

Dr. Bill Clark, Ph.D.
[email protected]
727-365-3420
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age 45-70 years at time of enrollment
Meets questionnaire-based inflammatory enrichment criteria (at least 2 of 5 risk factors, per Section 4.2)
Non-smoker (no tobacco or nicotine use within 6 months of enrollment)
Willing and able to maintain stable diet, exercise habits, and supplement use throughout the 24-week study period
No major medication changes planned during the study period
Willing to perform home-based DBS collections at T0, T12, and T24
Access to a smartphone or computer to complete eConsent and online questionnaires
Able to provide informed consent via the Alethios eConsent platform

Exclusion

Current use of prescription anti-inflammatory medications including NSAIDs (regular use ≥3x/week), corticosteroids, or DMARDs
Diagnosis of an autoimmune or inflammatory disease (e.g., rheumatoid arthritis, lupus, IBD, multiple sclerosis)
Active or unstable cardiovascular disease requiring medication changes during the study period
History of cancer within the past 5 years (except non-melanoma skin cancer)
Regular use of supplemental fisetin, quercetin, or resveratrol within 30 days of enrollment
Pregnancy, breastfeeding, or planning to become pregnant during the study
Known allergy to apple or apple-derived products
Body mass index (BMI) \>40 kg/m²

What this trial measures

  • Change from Baseline in High-Sensitivity C-Reactive Protein (hsCRP) at Week 24Baseline (Week 0) and Week 24

    Evaluation of systemic inflammation via high-sensitivity C-reactive protein levels quantified from dried blood spot micro-sampling.